← Back to Screener
Hologic Inc (HOLX)
Price$76.01
Favorite Metrics
Price vs S&P 500 (26W)13.91%
Price vs S&P 500 (4W)3.41%
Market Capitalization$16.97B
P/E Ratio (Annual)30.00x
All Metrics
P/CF (Annual)16.05x
Book Value / Share (Quarterly)$23.51
P/TBV (Annual)3.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.53%
Cash Flow / Share (Quarterly)$4.29
Price vs S&P 500 (YTD)5.41%
Gross Margin (TTM)56.51%
Net Profit Margin (TTM)13.18%
EPS (TTM)$2.41
10-Day Avg Trading Volume12.56M
EPS Excl Extra (TTM)$2.41
Revenue Growth (5Y)1.66%
EPS (Annual)$2.49
ROI (Annual)7.47%
Gross Margin (Annual)56.35%
Net Profit Margin (5Y Avg)20.94%
Cash / Share (Quarterly)$10.60
P/E Basic Excl Extra (TTM)31.20x
Revenue Growth QoQ (YoY)2.54%
EPS Growth (5Y)-10.02%
P/E Normalized (Annual)30.00x
ROA (Last FY)6.28%
Revenue Growth TTM (YoY)2.17%
EBITD / Share (TTM)$3.29
ROE (5Y Avg)21.35%
Operating Margin (TTM)17.56%
Cash Flow / Share (Annual)$4.06
P/B Ratio3.24x
P/B Ratio (Quarterly)3.17x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)4.20x
Net Interest Coverage (TTM)17.99x
ROA (TTM)6.12%
EPS Growth QoQ (YoY)-8.44%
EV / EBITDA (TTM)23.29x
EPS Incl Extra (Annual)$2.49
Current Ratio (Annual)3.75x
Quick Ratio (Quarterly)3.10x
3-Month Avg Trading Volume3.91M
52-Week Price Return23.21%
EV / Free Cash Flow (Annual)19.15x
P/E Incl Extra (TTM)31.20x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$21.06
P/S Ratio (Annual)4.14x
Asset Turnover (Annual)0.45x
52-Week High$76.07
Operating Margin (5Y Avg)26.65%
EPS Excl Extra (Annual)$2.49
CapEx CAGR (5Y)-0.52%
Tangible BV CAGR (5Y)26.13%
26-Week Price Return13.19%
Quick Ratio (Annual)2.87x
13-Week Price Return2.04%
Total Debt / Equity (Annual)0.50x
Current Ratio (Quarterly)4.04x
Enterprise Value$17,321.146
Revenue / Share Growth (5Y)4.77%
Asset Turnover (TTM)0.46x
Book Value / Share Growth (5Y)16.60%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.63x
Pretax Margin (Annual)16.61%
Cash / Share (Annual)$9.90
3-Month Return Std Dev2.63%
Gross Margin (5Y Avg)59.57%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-8.61%
EBITDA Interim CAGR (5Y)-22.64%
ROE (Last FY)11.21%
Net Interest Coverage (Annual)10.71x
EPS Basic Excl Extra (Annual)$2.49
P/FCF (TTM)17.73x
Receivables Turnover (TTM)6.79x
EV / Free Cash Flow (TTM)18.10x
Total Debt / Equity (Quarterly)0.48x
EPS Incl Extra (TTM)$2.41
Receivables Turnover (Annual)6.83x
ROI (TTM)7.29%
P/S Ratio (TTM)4.11x
Pretax Margin (5Y Avg)25.89%
Revenue / Share (Annual)$18.02
Tangible BV / Share (Annual)$20.03
Forward P/E16.99x
Free OCF CAGR (5Y)4.10%
Price vs S&P 500 (52W)0.44%
P/E Ratio (TTM)31.20x
EPS Growth TTM (YoY)-23.76%
Year-to-Date Return2.04%
5-Day Price Return0.61%
EPS Normalized (Annual)$2.49
ROA (5Y Avg)11.04%
Net Profit Margin (Annual)13.80%
Month-to-Date Return0.56%
Cash Flow / Share (TTM)$3.14
EBITD / Share (Annual)$3.23
EPS Growth (3Y)-21.46%
Operating Margin (Annual)17.42%
LT Debt / Equity (Annual)0.50x
P/CF (TTM)15.46x
ROI (5Y Avg)13.23%
P/E Excl Extra (TTM)31.20x
LT Debt / Equity (Quarterly)0.48x
EPS Basic Excl Extra (TTM)$2.41
P/TBV (Quarterly)3.54x
P/B Ratio (Annual)2.96x
Inventory Turnover (TTM)2.57x
Pretax Margin (TTM)16.08%
Book Value / Share (Annual)$22.68
Price vs S&P 500 (13W)5.41%
Net Margin Growth (5Y)-14.11%
Beta0.74x
P/FCF (Annual)18.76x
Revenue / Share (TTM)$18.27
ROE (TTM)11.01%
52-Week Low$51.90
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.40
2.78
2.78
2.78
Industry Peers — X-Ray Equipment(3)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
HOLXHologic Inc | 4.11x | 1.66% | 56.51% | 17.56% | $76.01 |
GEHCGE HealthCare Technologies Inc. Common Stock | 1.63x | 3.74% | 39.98% | 13.40% | $73.20 |
PHGKONINKLIJKE PHILIPS N.V. | 1.74x | 0.59% | 45.43% | 8.08% | $28.63 |
BFLYButterfly Network, Inc. | 12.68x | — | 46.85% | -88.53% | $5.29 |
About
Hologic manufactures women's healthcare products across four segments: diagnostics (44% of sales), breast health (38%), surgical (16%), and skeletal health (2%). The Gen-Probe acquisition strengthened its diagnostics business. The company generates 69% of revenue from the United States, with Europe (20%), Asia (8%), and other markets contributing the remainder.